Meeder Asset Management’s Denali Therapeutics DNLI Stock Holding History

Meeder Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-206	Closed	-$2.99K	–	926
2025 Q3	$2.99K	Buy	+206	New	+$2.96K	﹤0.01%	745
2025 Q1	–	Sell	-165	Closed	-$3.36K	–	937
2024 Q4	$3.36K	Buy	165 +6	+4%	+$154	﹤0.01%	872
2024 Q3	$4.63K	Buy	+159	New	+$3.94K	﹤0.01%	755
2021 Q4	–	Sell	-3,669	Closed	-$186K	–	1479
2021 Q3	$186K	Buy	3,669 +922	+34%	+$52K	0.01%	742
2021 Q2	$215K	Buy	2,747 +306	+13%	+$18.9K	0.01%	708
2021 Q1	$139K	Buy	+2,441	New	+$163K	0.01%	824
2020 Q4	–	Sell	-2,426	Closed	-$88K	–	1964
2020 Q3	$88K	Buy	2,426 +1,960	+421%	+$59K	0.01%	821
2020 Q2	$13K	Sell	466 -1,047	-69%	-$24.6K	﹤0.01%	1239
2020 Q1	$26K	Buy	+1,513	New	+$31.6K	﹤0.01%	1135
2019 Q1	–	Sell	-318	Closed	-$7K	–	1733
2018 Q4	$7K	Sell	318 -79	-20%	-$1.43K	﹤0.01%	1329
2018 Q3	$9K	Buy	+397	New	+$6.57K	﹤0.01%	1183

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meeder Asset Management's DNLI Position: Q4 2025 in Review

Meeder Asset Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 206 shares — an estimated $2.99K sold.

Meeder Asset Management first reported a position in DNLI in Q3 2018 and held it in 11 quarters. The position peaked at $215K in Q2 2021. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Meeder Asset Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Meeder Asset Management sold 206 Denali Therapeutics shares in Q4 2025, an estimated $2.99K.
Meeder Asset Management first reported a position in Denali Therapeutics in Q3 2018 and held it in 11 quarters.
Meeder Asset Management's Denali Therapeutics position peaked at $215K in Q2 2021.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Meeder Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.